ResearchMoz

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

GBI Research
Published Date » 2012-12-31
No. Of Pages » 72
     
  Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail  
     
  Summary  
   
 Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Liver Cancer Therapeutics Market to 2018 - Introduction 9

3 Liver Cancer Therapeutics Market to 2018 - Overview 10
3.1 Introduction 10
3.1.1 Benign Tumor 10
3.1.2 Primary Liver Cancer 10
3.1.3 Secondary Liver Cancer 10
3.2 Symptoms 11
3.3 Diagnosis 11
3.3.1 Laboratory Tests 11
3.3.2 Imaging Tests 11
3.3.3 Others 12
3.4 Treatment Options 12
3.4.1 Surgery 13
3.4.2 Non-surgical 13
3.4.3 General Treatment Algorithm 15
3.4.4 Treatment by Stage 16
3.4.5 New Technologies in Treatment 18

4 Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts 19
4.1 Revenue 19
4.2 Annual Cost of Therapy 22
4.3 Marketed Products 23
4.3.1 Nexavar 23
4.3.2 Miripla 25
4.4 Treatment Usage Pattern 27
4.4.1 Prevalence Population 28
4.4.2 Diagnosed Population 28
4.4.3 Prescription Population 28
4.5 Drivers and Barriers of Liver Cancer Therapeutics Market 28
4.5.1 Drivers 28
4.5.2 Barriers 29

5 Liver Cancer Therapeutics Market to 2018 - Geographical Landscape 30
5.1 US 30
5.1.1 Introduction 30
5.1.2 Revenue 30
5.1.3 Cost of Therapy 32
5.1.4 Treatment Usage Pattern 33
5.2 Top Five European Countries 34
5.2.1 Introduction 34
5.2.2 Revenue 34
5.2.3 Cost of Therapy 36
5.2.4 Treatment Usage Pattern 37
5.3 Japan 38
5.3.1 Introduction 38
5.3.2 Revenue 38
5.3.3 Cost of Therapy 39
5.3.4 Treatment Usage Pattern 40

6 Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis 41
6.1 Introduction 41
6.2 R&D Product Pipeline by Stage of Development 43
6.2.1 Phase III 43
6.2.2 Phase II/III 44
6.2.3 Phase II 44
6.2.4 Phase I/II 45
6.2.5 Phase I 46
6.2.6 Pre-Clinical 47
6.2.7 Discovery 47
6.3 Profiles of Promising Molecules 48
6.3.1 PrevOnco 48
6.3.2 Ramucirumab 48
6.3.3 ThermoDox 49
6.3.4 Afinitor 50

7 Liver Cancer Therapeutics Market to 2018 - Competitive Landscape 51
7.1 Bayer 51
7.2 Dainippon Sumitomo Pharma 52

8 Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations 53
8.1 Introduction 53
8.2 Deals by Geography 54
8.3 Deals by Year 55
8.4 Mergers and Acquisition Deals 56
8.4.1 Overview 56
8.4.2 Profiles of Major M&A Deals 57
8.5 Licensing Agreements 58
8.5.1 Overview 58
8.5.2 Profiles of Major Licensing Agreements 60
8.6 Co-Development Agreements 62
8.6.1 Overview 62
8.6.2 Profiles of Major Co-Development Agreements 63

9 Liver Cancer Therapeutics Market to 2018 - Appendix 64
9.1 Market Definitions 64
9.2 Abbreviations 64
9.3 Bibliography 66
9.4 Research Methodology 67
9.4.1 Coverage 67
9.4.2 Secondary Research 68
9.4.3 Primary Research 68
9.5 Therapeutic Landscape 69
9.5.2 Market Size by Geography 70
9.6 Geographical Landscape 71
9.7 Pipeline Analysis 71
9.8 Competitive Landscape 72
9.8.1 Expert Panel Validation 72
9.9 Contact Us 72
9.10 Disclaimer 72

List of Tables


Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011 19
Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018 19
Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011 20
Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018 21
Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011 22
Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018 22
Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results 23
Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial 24
Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History 25
Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2011 27
Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011-2018 27
Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011 30
Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018 31
Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011 32
Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018 32
Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2011 33
Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011-2018 33
Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011 35
Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018 35
Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011 36
Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018 36
Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2011 37
Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2011-2018 37
Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011 38
Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018 39
Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011 39
Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 39
Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2011 40
Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011-2018 40
Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 42
Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline 43
Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline 44
Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline 44
Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline 45
Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline 46
Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012 47
Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012 47
Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012 51
Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012 52
Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53
Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54
Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55
Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012 56
Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012 58
Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012 62

List of Figures


Figure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012 12
Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm 15
Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm 16
Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm 17
Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018 19
Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018 20
Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018 22
Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2018 27
Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012 29
Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018 30
Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018 32
Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2018 33
Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018 34
Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018 35
Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018 36
Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2018 37
Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018 38
Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018 39
Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2018 40
Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 41
Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53
Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54
Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55
Figure 24: GBI Research Market Forecasting Model 71

Upcoming Reports:

Greece: pickles market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the pickles market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the pickles market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Greece: vegetable oils market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the vegetable oils market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the vegetable oils market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of...
Intra Abdominal Infection Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
Intra abdominal infections are a group of diseases of abdomen and are one of the most common causes of mortalities across the globe. These include peritonitis, intra abdominal abscess, diverticulitis, appendicitis, food poisoning and pelvic inflammatory disease. Post surgical infections are a major cause of intra abdominal infections. The infections can also occur due to inflammatory bowel disease, ruptured appendix, and intestinal infection. Symptoms may vary depending on the anatomical location of infection. Common symptoms include abdominal pain, chills, diarrhea, nausea, lack of...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Technology License Deal Signed between Sumitomo Chemical and Universal Display
Jan 22, 2015  
A new OLED technology license agreement has been signed between Sumitomo Chemical Company Ltd., and Universal Display Corporation. This agreement states that non-exclusive license rights have been granted to Sumitomo Chemical by Universal Display. These rights come within the ambit of several patents that are controlled and owned by Universal Display for manufacturing and selling processed...
Utah: Ranks No. 2 in Toxic Chemical Emissions
Jan 22, 2015  
As per reports, it has been observed and concluded that Utah has the maximum number of open-pit copper mines in the entire world, and this involves huge volumes of lead compounds. The annual inventory of Environmental Protection Agency denotes that Utah holds the second position amidst 56 states and territories all over the country for toxic and harmful releases per square mile. ...
The Production of Bio-based Materials and Chemicals to Increase Significantly by 2018
Jan 22, 2015  
It is expected that the global production capacity of bio-based materials and chemicals will increase significantly by 2018. The growth will primarily be driven by growth taking place in Brazil, and the U.S. As a result, with the help of the emerging technologies the production will be greater than 7.4 million metric tons. Also, the market for bio-based materials and chemicals will be fueled...
Maxx Mobilink Announces its Plan to Manufacture in India
Jan 22, 2015  
Maxx Mobilink, Indian smartphone manufacturer intends to start making mobile handsets at its Haridwar plant. This plan will only materialize after the manufacturer has assembled devices starting April at its factory where it presently makes charger, batteries, and other such accessories. The mobile manufacturer’s plan is in accordance with Prime Minister’s appeal to the nation to...
Ontario to Benefit from Western Canadas Loss
Jan 22, 2015  
As oil prices are hitting a new low in Canada, the country cannot help but turn to Ontario to make some recovery. Presently, Ontario is Canada’s only hope to sustain its growth in manufacturing. It was in December last year that TD Economics predicted that Ontario will help Canada achieve growth at a rapid pace with a 2.6% hike in GDP in 2015. The current economic winds are suggestive of...